Table 1.

Representative Oncolytic Virus Clinical Trials in Progress (as of November 2016

PRIMARY OUTCOME	DRUGS	PI	CONDITION
Best overall response rate (BORR) [Time Frame: at 24 weeks] [Designated as safety issue: No]	Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab	Robert Andtbacka	Stage IIIB, Stage IIIC, or Stage IV Unresectable or Metastatic Malignant Melanoma
Maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by intravenous (IV) infusion [Time Frame: 4 weeks] [Designated as safety issue: Yes]	Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)	David Kim, MD	Melanoma Lung Cancer Renal Cell Carcinoma
Safety and tolerability of two doses of Coxsackievirus A21 administered intratumourally. [Time Frame: Days 1, 3, 6, 8,10, 13, 17, 24, 38, 52, 87] [Designated as safety issue: Yes]	Coxsackievirus A21	Mark Smithers Damien Thomson	Stage IV Melanoma
Number of participants with treatment-related adverse events as defined by CTCAE v4.03. [Time Frame: 2.5 years] [Designated as safety issue: Yes]	Biological: GL-ONC1 Biological: Eculizumab	Kaitlyn Kelly	Solid Organ Cancers
Response rate for injected tumor(s) [Time Frame: Initial response assessment at 6 weeks] [Designated as safety issue: No]	Biological: JX-594	James Burke	Melanoma
Safety and tolerability (CTCAE version 4.0). [Time Frame: up to Week 16] [Designated as safety issue: Yes] Adverse events will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0).	Biological: TBI-1401(HF10)	Naoya Yamazaki	Solid Tumor
Phase I: Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) [Time Frame: Up to 6 months] [Designated as safety issue: Yes] MTD/RP2D of talimogene laherparepvec administered with neoadjuvant paclitaxel-doxorubicin/cyclophosphamide	Biological: Talimogene laherparepvec Drug: Paclitaxel	Hatem Soliman	Breast Cancer Ductal Carcinoma Invasive Breast Carcinoma Invasive Ductal Breast Carcinoma
To determine whether intratumoral injection or intravenous infusions of HSV1716 is safe in adolescents and young adults with non-CNS solid tumors. [Time Frame: Dose limiting toxicities will be assessed at 28 days after injection of HSV1716.] [Designated as safety issue:	Biological: HSV1716	Timothy Cripe	Rhabdomyosarcoma Osteosarcoma Ewing Sarcoma Soft Tissue Sarcoma
The incidence of dose-limiting toxicities (DLT) of intravenous pembrolizumab in combination with intratumoral CAVATAK will be assessed using CTCAE v. 4.0. [Time Frame: Up to 2 years] [Designated as safety issue: Yes]	Biological: CAVATAK Drug: Pembrolizumab	Howard L Kaufman	Melanoma